Media & News
The untold stories about the biggest statistical outliers.
Daily coverage of the founders, funds and moves that matter, covered from the inside out.
Journal & posts.
Long reads from the Outliers journal and the posts that travelled furthest on LinkedIn.
Everyone’s talking about Flatpay. Nobody’s talking about the exit Sander Janca-Jensen just made.
Same team, same recipe, five industries in six years: from Måtteservice Danmark to a €1.5B unicorn and an exit to the listed Swiss giant Sonova. A look at the playbook behind one of Denmark’s most repeatable founders.
Read the full story →
Is venture capital turning into a monopoly game?
Established firms took 88.2% of US venture fundraising in 2026, a PitchBook record, and six platforms now manage around $440B. Is venture heading for an oligopoly, or is this the moment for small, contrarian funds?
Read the full story →1 min read
Lucy Guo never invested in Anthropic, yet she ended up as a significant shareholder.
Her fund backed a startup that Anthropic later acquired and paid for in stock. With an IPO expected at $2T or more, the “luckiest thing ever” could be worth close to $100M.
Read the full story →1 min read
AMD just spent $8.2B on a recruitment.
World Labs was founded in 2024 and just sold to AMD for $8.2B in stock, making Fei-Fei Li Chief Scientist. The ImageNet pioneer has now been early twice.
Read the full story →1 min read
Netflix and OpenAI pay up to $775,000 a year for storytellers. It’s time to rethink the job.
Most companies have 4–5 big moments a year, yet the feed asks for something new every week. That gap is why we need story creators, not storytellers.
Read the full story →1 min read
$47B gone. A $350M check to try again. Could Adam Neumann’s comeback happen in Europe?
In the US, failure reads as experience. In Europe, it reads as a permanent record. Why only one continent hands founders a second act, and why Neumann is now telling the story himself.
Read the full story →1 min read
This Danish chemist’s idea has generated $110 billion in revenue.
Lotte Bjerre Knudsen saw obesity in a diabetes molecule two decades before anyone believed her. Today semaglutide, behind Wegovy and Ozempic, is over 70% of what Novo Nordisk sells.
Read the full story →1 min read
The Outliers Podcast
Stories from Unicorn founders, Top GPs and the biggest statistical outliers.
New episode every Tuesday. The decisions, the numbers and the years that nobody puts in a keynote.
Latest episodes.
- Episode 01Get the Fucking MoneyHe sold for nine figures at thirty four and spent the next year unsure what he was for.1h 24m
- Episode 02The Double Unicorn FounderHe built 2 unicorns and now he is on to the next.1h 08m
- Episode 03Exits and BubblesSix years of being told the market did not exist, and the quarter it finally did.1h 41m